Senores Pharmaceuticals Limited — Board Meeting, 15-05-2025: Outcome of Board Meeting

Senores Pharmaceuticals reported a strong FY25 with consolidated revenue rising 91% to Rs. 410 Cr and profit before tax up 183% at Rs. 71 Cr. Regulated market sales hit Rs. 245 Cr (+69%), boosted by ANDA portfolio growth and CDMO/CMO operations, while emerging markets jumped 174% to Rs. 121 Cr with better margins. The company acquired 15 ANDAs, mostly tied to government contracts, and launched a new CDMO/CMO product. Rs. 500 Cr IPO proceeds partly deployed in subsidiaries and working capital. Leadership changes include a new GM-Production and R&D AVP resignation.